Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17608163 | 0.81 | AURKA (0.38) | NPC1RAB9ASMN1; SMN2AURKAPDPK1 | |
| SCHEMBL4852024 | 0.74 | NOTUM (0.39) | ADORA2AADORA1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30129593 | 0.71 | MAP4K4 (0.46) | — | |
| SCHEMBL22191645 | 0.71 | MAP4K4 (0.46) | — | |
| SCHEMBL11231763 | 0.71 | PDE3B (0.46) | ADORA2AADORA1NPC1AURKAPDPK1 | |
| SCHEMBL19367479 | 0.70 | CRHBP (0.55) | ADORA2AADORA1SMN1; SMN2PDPK1MAPT | |
| SCHEMBL1143098 | 0.69 | SMN1; SMN2 (0.61) | ADORA2AADORA1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1143959 | 0.69 | ALPL (0.54) | NPC1RAB9ASMN1; SMN2L3MBTL1MAPT | |
| SCHEMBL19367478 | 0.69 | NPC1 (0.37) | NPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL23407772 | 0.68 | RAB9A (0.41) | NPC1RAB9ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170267656-A1 | PYRAZOLYL-SUBSTITUTED PYRIDONE COMPOUNDS AS SERINE PROTEASE INHIBITORS | VERSEON INTERNATIONAL CORPORATION | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267656-A1 | PYRAZOLYL-SUBSTITUTED PYRIDONE COMPOUNDS AS SERINE PROTEASE INHIBITORS | SERPINE1, PRSS1, SPINT2 | ADORA2A 3344/4885ADORA1 3325/4885NPC1 3346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.